RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings

Cell Research

Volumn 22, Issue 5, 2012, Pages 806-821

  Ren, Shancheng ^a   Peng, Zhiyu ^b   Mao, Jian Hua ^c   Yu, Yongwei ^a   Yin, Changjun ^d   Gao, Xin ^e   Cui, Zilian ^a   Zhang, Jibin ^b   Yi, Kang ^b   Xu, Weidong ^a   Chen, Chao ^b   Wang, Fubo ^a   Guo, Xinwu ^b   Lu, Ji ^a   Yang, Jun ^b   Wei, Min ^a   Tian, Zhijian ^b   Guan, Yinghui ^c   Tang, Liang ^a   Xu, Chuanliang ^a   Wang, Linhui ^a   Gao, Xu ^a   Tian, Wei ^b   Wang, Jian ^b   Yang, Huanming ^b   Wang, Jun ^b   Sun, Yinghao ^a   more..

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BGI SHENZHEN   (China)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d NANJING MEDICAL UNIVERSITY   (China)

^e THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

alternative splicing; gene fusions; long ncRNAs; prostate cancer; RNA sequencing

Indexed keywords

CTAGE5 PROTEIN, HUMAN; ERG PROTEIN, HUMAN; KHDRBS3 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA BINDING PROTEIN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR PROTEIN; UBIQUITIN THIOLESTERASE; UNTRANSLATED RNA; USP9Y PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; CHEMISTRY; CHINA; CHROMOSOME 21; COHORT ANALYSIS; GENE FUSION; GENETICS; HUMAN; HUMAN GENOME; MALE; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; RECURRENT DISEASE; SEQUENCE ANALYSIS;

ALTERNATIVE SPLICING; ANTIGENS, NEOPLASM; BASE SEQUENCE; CHINA; CHROMOSOMES, HUMAN, PAIR 21; COHORT STUDIES; GENE FUSION; GENOME, HUMAN; HUMANS; MALE; MUTATION; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECURRENCE; RNA, UNTRANSLATED; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, RNA; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TRANSCRIPTOME; UBIQUITIN THIOLESTERASE;

EID: 84862777104     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.30     Document Type: Article

References (70)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41:834-845.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300.
4. Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42:751-754.
5. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41:781-793.
6. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24:1967-2000.
7. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22.
8. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-209.
9. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101:811-816.
10. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67:8504-8510.
11. Kim JH, Dhanasekaran SM, Mehra R, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007; 67:8229-8239.
12. Mendes A, Scott RJ, Moscato P. Microarrays-identifying molecular portraits for prostate tumors with different Gleason patterns. Methods Mol Med 2008; 141:131-151.
13. Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now? J Pathol 2011; 223:318-326.
14. Morozova O, Marra MA. Applications of next-generation sequencing technologies in functional genomics. Genomics 2008; 92:255-264.
15. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009; 55:641-658.
16. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63.
17. Ozsolak F, Milos PM. RNA sequencing: Advances, challenges and opportunities. Nat Rev Genet 2011; 12:87-98.
18. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol 2010; 220:231-243.
19. Ding L, Wendl MC, Koboldt DC, Mardis ER. Analysis of next-generation genomic data in cancer: Accomplishments and challenges. Hum Mol Genet 2010; 19:R188-R196.
20. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11:685-696.
21. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cyto genetically normal acute myeloid leukaemia genome. Nature 2008; 456:66-72.
22. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467:1109-1113.
23. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465:473-477.
24. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424-2433.
25. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
26. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010; 464:999-1005.
27. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-196.
28. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330:228-231.
29. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462:1005-1010.
30. Griffith M, Griffith OL, Mwenifumbo J, et al. Alternative expression analysis by RNA sequencing. Nat Methods 2010; 7:843-847.
31. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa- cell tumors of the ovary. N Engl J Med 2009; 360:2719-2729.
32. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363:1532-1543.
33. Maher CA, Palanisamy N, Brenner JC, et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA 2009; 106:12353-12358.
34. Zhao Q, Caballero OL, Levy S, et al. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci USA 2009; 106:1886-1891.
35. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458:97-101.
36. Li R, Yu C, Li Y, et al. SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics 2009; 25:1966-1967.
37. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-648.
38. Pflueger D, Terry S, Sboner A, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011; 21:56-67.
39. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
40. Esgueva R, Perner S, J LaFargue C, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23:539-546.
41. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-1076.
42. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6:255-261.
43. Ifere GO, Ananaba GA. Prostate cancer gene expression marker 1 (PCGEM1): A patented prostate-specific non-coding gene and regulator of prostate cancer progression. Recent Pat DNA Gene Seq 2009; 3:151-163.
44. Nagano T, Mitchell JA, Sanz LA, et al. The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008; 322:1717-1720.
45. Loewer S, Cabili MN, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet 2010; 42:1113-1117.
46. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-693.
47. Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002; 71:817-846.
48. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463:364-368.
49. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24:2343-2364.
50. McCracken M, Olsen M, Chen MS, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007; 57:190-205.
51. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16:793-798.
52. Van Landuyt L, Lissens W, Stouffs K, et al. The role of USP9Y and DBY in infertile patients with severely impaired spermatogenesis. Mol Hum Reprod 2001; 7:691-693.
53. Lee KH, Song GJ, Kang IS, et al. Ubiquitin-specific protease activity of USP9Y, a male infertility gene on the Y chromosome. Reprod Fertil Dev 2003; 15:129-133.
54. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326:1230.
55. Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42:668-675.
56. Lin C, Yang L, Tanasa B, Hutt K, et al. Nuclear receptorinduced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139:1069-83.
57. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29:742-749.
58. Kannan K, Wang L, Wang J, et al. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 2011; 108:9172-7.
59. Orom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010; 143:46-58.
60. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009; 6:454-460.
61. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009; 60:139-151.
62. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome Res 1997; 7:986-995.
63. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863-14868.
64. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004; 20:3246-3248.
65. Li RQ, Li YR, Fang XD, et al. SNP detection for massively parallel whole-genome resequencing. Genome Res 2009; 19:1124-1132.
66. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72:291-336.
67. Lareau LF, Green RE, Bhatnagar RS, Brenner SE. The evolving roles of alternative splicing. Curr Opin Struct Biol 2004; 14:273-282.
68. Stamm S, Ben-Ari S, Rafalska I, et al. Function of alternative splicing. Gene 2005; 344:1-20.
69. Huang S, Zhang J, Li R, et al. SOAPsplice: genome-wide ab initio detection of splice junctions from RNA-Seq data. Front Genet 2011; 2:46.
70. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66:3396-3400.